Canada’s federal prison service is facing a growing backlash from psychiatrists, pharmacists and prisoner advocates over changes to the national drug formulary that governs which medicines are routinely available to roughly 14,000 people in federal custody.
Mental health specialists say the revised list—rolled out across institutions in recent months—restricts access to several commonly prescribed psychiatric medications and substitutes others with narrower indications or more burdensome monitoring requirements. Clinicians working in and alongside the prison system argue the approach departs from widely accepted psychiatric standards, risks destabilising patients with severe mental illness, and could increase self-harm and behavioural crises inside institutions.
At the centre of the dispute is the Correctional Service of Canada’s effort to standardise prescribing and control costs, while also reducing diversion and misuse of certain drugs in prisons. In policy briefings and internal guidance circulated to staff, the service has emphasised patient safety, security and “evidence-informed” prescribing.
But critics say the new formulary is less a clinical update than a blunt administrative tool that fails to account for the realities of psychiatric care in locked settings, where rates of trauma, substance use disorders and complex comorbidity are higher than in the general population. Research on correctional health consistently shows that mental illness is over-represented in prisons, with elevated prevalence of major depression, psychotic disorders and post-traumatic stress symptoms, and that continuity of medication is a key protective factor during incarceration.
Several clinicians interviewed for this report described scenarios in which stable patients were asked to switch medications for non-medical reasons or faced delays obtaining non-formulary drugs that previously could be accessed through routine specialist justification. They warn that even short interruptions—particularly with antidepressants, antipsychotics or mood stabilisers—can precipitate withdrawal symptoms, relapse, insomnia and agitation, all of which can raise risk in overcrowded units.
“There’s a difference between prudent prescribing and forced substitution,” said one psychiatrist who has treated federally incarcerated patients and requested anonymity because of professional constraints. “When you destabilise people in a high-stress environment, you don’t just risk their health—you change the safety dynamics of the whole institution.”
Pharmacists and psychiatric nurses have raised related concerns: that formulary restrictions may drive increased use of sedating alternatives that are easier to stock but may carry higher metabolic or cognitive side effects, undermining rehabilitation and daily functioning. Studies in forensic psychiatry have linked inappropriate medication changes to poorer therapeutic engagement and increased acute-care transfers, outcomes that can be costly as well as clinically harmful.
Prisoner legal advocates argue the policy could expose the federal government to challenges on the grounds that incarcerated people are entitled to medically necessary care comparable to community standards. Canadian courts have previously scrutinised gaps in prison health provision, and international human-rights guidance emphasises “equivalence of care” between prisons and the community.
Correctional authorities, for their part, point to longstanding problems with medication diversion inside prisons, where some drugs can become de facto currency and contribute to intimidation and violence. They also cite concerns about overprescribing of certain sedating or dependence-forming medications and the need for consistent protocols across institutions that vary widely in staffing.
Yet experts in correctional medicine say diversion control is best addressed through supervised dispensing, addiction treatment access, and stronger mental health staffing—not simply narrowing formularies. “You can’t solve a clinical and security problem by making the clinical toolkit smaller,” said a clinician familiar with prison health policy. “It tends to displace risk rather than reduce it.”
The dispute is also unfolding against a broader global reassessment of how states manage vulnerable people in custody. Recent high-profile controversies in the United States around execution protocols and medical ethics have intensified scrutiny of health care behind bars, with legal scholars warning that novel or “unprecedented” state decisions can land on uncertain legal footing. While Canada’s situation is different—centred on access to treatment rather than capital punishment—the common thread is the tension between security imperatives and medical standards.
Mental health groups are now urging Ottawa to pause implementation and establish an independent clinical review, including external psychiatrists and pharmacists with experience in forensic settings. They want transparent criteria for non-formulary approvals, clear protections for patients who are stable on existing regimens, and better data on adverse events, including hospitalisations, self-harm incidents and use-of-force episodes following medication changes.
Without such safeguards, critics fear the formulary revisions could unintentionally worsen an already fragile mental health landscape in federal prisons—where long wait times for therapy, limited specialist access and high rates of isolation-related distress are frequently reported in research.
Why it matters
Medication policies in prisons shape not only individual health outcomes but also safety and stability across entire institutions. If access to effective psychiatric treatment is narrowed without robust clinical safeguards, preventable crises may rise—driving up hospital transfers, staff injuries and long-term disability. The controversy also tests Canada’s commitment to providing health care in custody that meets community standards.